Patent 7776523 was granted and assigned to Novartis on August, 2010 by the United States Patent and Trademark Office.
Human endogenous retroviruses of the HML-2 family show up-regulated expression in prostate tumors. This finding can be used in prostate cancer screening, diagnosis and therapy.